Glycyrrhizin attenuates tissue injury and reduces neutrophil accumulation in experimental acute pancreatitis.

Leukocyte infiltration and acinar cell injury are characteristic features of acute pancreatitis (AP). However, the signaling pathways regulating inflammation and accumulation of leukocytes into pancreas tissue remains poorly elucidated. In the current study, we investigated the effects of Glycyrrhizin (GZ) on cerulein-induced AP in mice. AP was induced in male C57BL/6 by intraperitoneal injection of 50 µg/kg cerulein hourly, with a total of 7 times. 1 hour after the last injection of cerulean, mice were treated with either 35 or 70 mg/kg of GZ. Serum amylases and lipases were measured using automated chromogenic assay, MCP-1 and MIP-2 concentrations were measured in the serum by ELISA, and the number of infiltrated inflammatory cells in the pancreas were evaluated by flow cytometry. We found that GZ treatment resulted in reduction (i) both amylase and lipase activities, (ii) the serum levels of both MCP-1 and MIP-2; and (iii) markedly attenuated cerulein-induced histopathological alternations and water contents. Furthermore, we observed that GZ significantly decreased the number of infiltrated monocytes and neutrophils into the pancreas tissue. In conclusion, we demonstrate that GZ attenuates AP signs and inhibits inflammatory cell recruitments into pancreas.

Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.

To evaluate demographic, clinical and laboratory features associated with scleroderma-specific auto-antibodies. Sera of 100 patients with systemic sclerosis (SSc) were analyzed by an indirect immunofluorescence technique with HEp-2 cells as a substrate. Specific ANA such as anti-centromere antibodies (ACA), anti-topoisomerase (TOPO), anti-RNA polymerase III (Pol 3), anti-U3-RNP (U3-RNP), anti-Th/To (Th/To) and anti-PM/Scl (PM/Scl) were detected by line immunoassay and anti-U1-RNP (U1-RNP) by ELISA. Frequency of clinical features associated with a specific antibody group was reported cumulatively over the follow-up period. Frequency of specific clinical features was compared across the two disease subtype including limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) as well as the auto-antibody groups. Ninety-four percent of patients were ANA positive with significant higher skin score, Raynauds and digital ulcer/gangrene. Anti-TOPO was detected in 71% of all patients, in 90.5% of dcSSC and in 65.8% of lcSSc. Anti-TOPO was significantly associated with dcSSc, higher skin score, digital ulcer/gangrene, pulmonary fibrosis, DLCO <70%. U1-RNP antibody was associated with lower fibrosis in lung. ACA was positive in 7% of patients and exclusively in those with lcSSc. We did not find association between gender and presence of auto-antibodies. Anti-TOPO antibody had a high prevalence in contrast to low prevalence of ACA antibody. There were no differences in clinical subtypes of the disease in patients with positive anti-TOPO and positive ACA. Differences in prevalence of auto-antibodies are suggestive of further genetic study.